

# MARKER THERAPEUTICS

## Lymphodepletion Improves the Expansion and Persistence of MAR-T Cells in Patients with Lymphoma

---

May 20, 2025

NASDAQ: MRKR



# Forward Looking Statements


Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions, including without limitation statements regarding Marker Therapeutics, Inc.’s (“Marker” or the “Company”) intentions, beliefs, projections, outlook, analyses or current expectations are “forward-looking statements”. Forward-looking statements include statements concerning, among other things: the Company’s research, development and regulatory activities and expectations relating to its non-engineered multi-antigen recognizing (MAR) T cell therapies; the effectiveness of the Company’s programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of the Company’s clinical trials of its product candidates, including MT-401 for the treatment of patients with Acute Myeloid Leukemia (“AML”) or Myelodysplastic Syndrome (“MDS”), MT-401 Off-the-Shelf (“OTS”) for the treatment of patients with AML, and MT-601 for the treatment of patients with relapsed lymphoma; the Company’s long-term stability and cash runway; the Company’s optimized manufacturing process; and the future development of MAR-T cell therapies (formerly known as multiTAA-specific T cells). Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Forms 10-K, 10-Q and other SEC filings which are available through EDGAR at [WWW.SEC.GOV](http://WWW.SEC.GOV). No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principals, partners, subsidiaries or affiliates, or any of such person’s board members, officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. Certain information set forth herein includes estimates, projections and targets and involves significant elements of subjective judgement and analysis, which may or may not be correct. No representations are made as to the accuracy of such estimates, projections or targets or that all assumptions relating to such estimates, projections or targets have been considered or stated or that such estimates, projections or targets will be realized. This presentation does not purport to contain all of the information that may be required to evaluate the Company and any recipient hereof should conduct its own independent analysis of the Company and the data and information contained herein. Any forward-looking statements are not guarantees of future performance and actual results may differ materially from estimates in the forward-looking statements. Unless otherwise stated, all information in this presentation is as of the date of the cover page of this presentation, and the Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

# Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing (MAR)-T Cells in Patients with Lymphoma

Preliminary immunomonitoring data from the Phase 1 APOLLO study suggest that lymphodepletion supports the expansion and persistence of MT-601 (a MAR-T cell product targeting 6 tumor-specific antigens) *in vivo*.

Using T Cell Receptor (TCR) sequencing as an immunomonitoring strategy, Marker has evidence suggesting that MT-601 MAR-T cell clones in the drug product expanded and persisted at significantly higher levels in study participants receiving lymphodepletion (red line) compared to participants who did not undergo the conditioning regimen (blue line).

Solid lines show the mean TCR expansion; dotted lines and shaded area represent the lower and upper range across all samples. The vertical dashed line at 4 weeks indicates the earliest observed clinical responses.



\*Objective clinical responses observed as early as 4 weeks after infusion of MT-601.

# THANK YOU